[gw22-e0514]

PGC-1 α GLY482SER POLYMORPHISM INCREASES THE SUSCEPTIBILITY TO NAFLD IN TYPE 2 DIABETIC PATIENTS

Chen Yanming, Shengqing, Xixiang, Ren Zhuozhuo, Wang Manman, Zeng Longyi *Department of Endocrinology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China*

10.1136/heartjnl-2011-300867.47

Background and aim The aim of this study is to investigate the relationship between peroxisome proliferators-activated receptor γ coactivator-1 α (PGC-1 α) Gly482Ser polymorphism and non-alcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2DM), and to clarify the effect of this gene variant on the transcription of cytosolic phosphoenolpyruvate carboxykinase (PEPCK-C) gene.

Methods According to typical liver ultrasonographic findings, 70 NAFLD with newly-diagnosed T2DM patients, 74 NAFLD patients, 70 newly-diagnosed T2DM patients and 84 NGT subjects were recruited into this study. PCR-restriction fragment length polymorphism (PCR-RFLP) was used to analyse the genotype of each individual. Then wild-type and mutated plasmids of PGC-1 α were transfected respectively into liver cells and the mRNA and protein levels of PEPCK-C and PEPCK-C promoter activity were detected after transfection.

Results We demonstrated that NAFLD patients were more obese and insulin resistant. PGC-1 α Ser482Ser genotype frequency and Ser482 allele frequency were higher in NAFLD patients complicated with T2DM than NGT group ($p < 0.05$). Objects possess this genotype had lower plasma HDL-C levels but higher LDL-C levels and had higher risk for NAFLD complicated with T2DM. And the PEPCK-C mRNA and protein levels in co-transfecting PGC-1 α (G) and HNF4 α plasmids group increased more than PGC-1 α (S) plus HNF4 α group ($p < 0.05$). Moreover, PGC-1 α (G) increased PEPCK-C promoter activity with 2.0-fold and 2.2-fold versus PGC-1 α (S) in HepG2 and LO2 cells respectively ($p < 0.05$).

Conclusion PGC-1 α Gly482Ser variant contributed to the onset of NAFLD in type 2 diabetic patients probably through impairing PEPCK-C gene transcription and exacerbating fat deposition.